Yesterday the Democratic Republic of the Congo (DRC) said that ministry of health and government officials have agreed that Merck’s rVSV-ZEBOV is the only vaccine that will be used during the current, ever-growing Ebola outbreak in North Kivu and Ituri provinces.
“Due to the lack of sufficient scientific evidence on the efficacy and safety of other vaccines as well as the risk of confusion among the population, it was decided that no clinical vaccine trials will be allowed throughout the country,” the ministry said in its daily update yesterday.
As of yesterday, a total of 158,830 people have been vaccinated with rVSV-ZEBOV, which clinical data suggest has as high as a 97.5% effectiveness rate against the virus.
Read more at CIDRAP…
Jul 11 DRC report
WHO Ebola dashboard
Jul 11 New Humanitarian article
Apr 15 CIDRAP News story “Ebola cases climb by 44 as vaccine trial affirms high efficacy”